Study on ligustrazine in reversing multidrug resistance of HepG2/ADM cell in vitro / 中国中药杂志
China Journal of Chinese Materia Medica
; (24): 970-973, 2004.
Article
de Zh
| WPRIM
| ID: wpr-293659
Bibliothèque responsable:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To study the reverse effect of ligustrazine (TMP) on HepG2/ADM, a herd of hepatocellular carcinoma cell, multidrug resistance (MDR) and the influence of P-gp170 expression.</p><p><b>METHOD</b>The reverse effect of ligustrazine on HepG2/ADM cell was observed, with the methods of cell culture, MTT's analyze, RT-PCR and Flow cytometric, etc.</p><p><b>RESULT</b>Ligustrazine could make MDR of cell line of HepG2/ADM reduce the expression of P-gp170, enhance the density of adriamycin in cell and increase the adriamycin's cytotoxicity. With the Flow cytometric, the results of RT-PCR showed the transcriptional activity of the MDR1 decreased.</p><p><b>CONCLUSION</b>Ligustrazine can reverse MDR of HCC cell line of HepG2/ADM and has prospect in clinical use.</p>
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Anatomopathologie
/
Pharmacologie
/
Pyrazines
/
Inhibiteurs des canaux calciques
/
Glycoprotéines
/
Doxorubicine
/
Carcinome hépatocellulaire
/
Multirésistance aux médicaments
/
Résistance aux médicaments antinéoplasiques
/
Gènes MDR
Limites du sujet:
Humans
langue:
Zh
Texte intégral:
China Journal of Chinese Materia Medica
Année:
2004
Type:
Article